1. Home
  2. WLK vs QGEN Comparison

WLK vs QGEN Comparison

Compare WLK & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westlake Corporation

WLK

Westlake Corporation

HOLD

Current Price

$78.64

Market Cap

10.3B

Sector

Industrials

ML Signal

HOLD

Logo Qiagen N.V.

QGEN

Qiagen N.V.

HOLD

Current Price

$44.75

Market Cap

8.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLK
QGEN
Founded
1986
1986
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3B
8.7B
IPO Year
2004
1998

Fundamental Metrics

Financial Performance
Metric
WLK
QGEN
Price
$78.64
$44.75
Analyst Decision
Buy
Buy
Analyst Count
15
8
Target Price
$106.87
$45.76
AVG Volume (30 Days)
1.2M
2.7M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
1.90%
7.17%
EPS Growth
N/A
N/A
EPS
0.70
N/A
Revenue
$11,170,000,000.00
N/A
Revenue This Year
$5.51
$8.18
Revenue Next Year
$3.74
$5.71
P/E Ratio
$113.50
$24.01
Revenue Growth
N/A
N/A
52 Week Low
$56.33
$32.53
52 Week High
$124.23
$57.82

Technical Indicators

Market Signals
Indicator
WLK
QGEN
Relative Strength Index (RSI) 53.69 67.59
Support Level $77.58 $44.61
Resistance Level $90.28 $46.17
Average True Range (ATR) 2.96 1.02
MACD 0.39 0.09
Stochastic Oscillator 84.04 87.45

Price Performance

Historical Comparison
WLK
QGEN

About WLK Westlake Corporation

Westlake is a forward-integrated commodity chemicals firm based in Houston. It began as a single low-density polyethylene plant and expanded its capabilities to include ethylene, vinyl chloride monomers, and polyvinyl chloride over the next two decades. The acquisition of Axiall in 2016 made it a North American leader in chlor-alkali and PVC. Today, Westlake has two defined segments: performance and essential materials, and housing and infrastructure products. The HIP segment began operating in 2022 following a series of acquisitions in the building products space. The firm aims to maximize the value of its chemical production by integrating with the HIP segment, realizing the higher margins of finished commercial goods.

About QGEN Qiagen N.V.

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

Share on Social Networks: